June 23 symposium talks centered on how gut and tumor-resident bacteria can shape cancer immunotherapy, with researchers arguing the microbiome is a treatment target rather than just background biology.
Marcel van den Brink said protecting commensal anaerobes may improve outcomes after allogeneic transplant, as chemotherapy- or radiation-damaged gut lining can fuel Enterococcus overgrowth linked to graft-versus-host disease.
Nicholas Arpaia outlined engineered probiotic strategies, including synchronized lysis circuits that repeatedly release immune-stimulating payloads inside tumors after intravenous, intratumor or oral delivery.
Susan Bullman said Fusobacterium nucleatum in gastrointestinal tumors is tied to relapse, metastasis and poor prognosis, and may push cancer cells into a quiescent, low-antigen state that blunts immune detection and could affect chemotherapy response.
Together, the presentations pointed to a broader shift in oncology: treating cancer within its microbial ecosystem and mapping host-bacteria interactions to guide future therapies.
If some bacteria help tumors hide and others help fight them, how can we choose the right microbial ally for each patient?
Can we weaponize 'good' bacteria to unmask cancer cells that other microbes have rendered invisible to our immune system?
Unveiling the Microbiome’s Power: 2026 Symposia and the U.S. Cancer Moonshot Initiative
Overview
In 2026, leading experts gathered at major scientific symposia to highlight the human microbiome’s critical role in cancer risk, immune function, and treatment response. This growing consensus marks a thrilling time for medicine and public health, as the microbiome is now seen as a groundbreaking innovation in understanding the human body. Events like City of Hope’s symposium underscored how microbiome research is shaping the future of cancer prevention and care, reflecting a pivotal shift in both scientific understanding and national health priorities.